ACM
INMB icon

Altium Capital Management’s INmune Bio INMB Stock Holding History

Altium Capital Management’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-52,257
Closed -$918K – 143
2021
Q2 		$918K Buy
+52,257
New +$704K 0.21% 113

Other funds holding INMB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Altium Capital Management's INMB Position: Q3 2021 in Review

Altium Capital Management sold out of INmune Bio (INMB) in Q3 2021, closing a stake of 52,257 shares — an estimated $918K sold.

Altium Capital Management first reported a position in INMB in Q2 2021 and held it in 1 quarter. The position peaked at $918K in Q2 2021. 41 funds tracked by Wall St. Rank hold INMB as of Q3 2021.

  • Altium Capital Management reported no remaining INmune Bio position as of Q3 2021 after selling out during the quarter.
  • Altium Capital Management sold 52,257 INmune Bio shares in Q3 2021, an estimated $918K.
  • Altium Capital Management first reported a position in INmune Bio in Q2 2021 and held it in 1 quarter.
  • Altium Capital Management's INmune Bio position peaked at $918K in Q2 2021.
  • 41 funds tracked by Wall St. Rank held INmune Bio as of Q3 2021.

Based on Altium Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.